What is Ohmx?
Ohmx, based in Evanston, IL, is a clinical diagnostics company dedicated to creating an accurate, reliable, and cost-effective comprehensive point-of-care (POC) system. This platform is designed to quantify analytes from minimal biological sample volumes. Ohmx's technology is notable for its potential to offer a wide array of POC tests for screening, monitoring, and detecting both acute and chronic diseases. The company's initial go-to-market product is a C-Reactive Protein (CRP) test, which aids physicians in identifying inflammation and determining the appropriateness of antibiotic treatment. Furthermore, the Ohmx test measures hsCRP levels for cardiovascular risk stratification. The company is actively developing additional assays for its bioelectronic platform, aiming to enhance patient care quality and provide new revenue streams for medical practices.
How much funding has Ohmx raised?
Ohmx has raised a total of $3M across 1 funding round:
Debt
$3M
Debt (2017): $3M, investors not publicly disclosed
What's next for Ohmx?
With a foundation built on major enterprise-level funding and strategic investment, Ohmx is poised for significant growth and market penetration. The company's focus on a versatile bioelectronic platform for POC diagnostics, starting with critical tests like CRP, positions it to address unmet needs in disease management and preventative care. Future developments are expected to expand the assay menu, further solidifying Ohmx's role as a key innovator in the diagnostics sector. The company's strategic direction likely involves scaling its manufacturing capabilities and expanding its commercial reach to healthcare providers seeking advanced, efficient diagnostic tools.
See full Ohmx company page
